Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Drugs that Affect Cardiac Metabolism: focus on Perhexiline|
|Citation:||Cardiovascular Drugs and Therapy, 2016; 30(4):399-405|
|Cher-Rin Chong, Benedetta Sallustio, John D. Horowitz|
|Abstract:||Approaches to the pharmacotherapy of angina pectoris have previously centred on the concept that a transient imbalance between myocardial oxygen "demand" and supply within the myocardium can best be addressed by reducing demand (for example, with β-adrenoceptor antagonist) or by increasing availability of blood (via coronary vasomotor reactivity adjustment or coronary revascularization). However, this principle is potentially challenged by the emergence of cases of angina unsuitable for such therapies (for example because of concomitant severe systolic heart failure) and by the recognition that impaired myocardial energetics may precipitate angina in the absence of fixed or variable coronary obstruction (for example in hypertrophic cardiomyopathy). The past 20 years have seen the re-emergence of a class of anti-anginal agents which act primarily by improving efficiency of myocardial oxygen utilization, and thus can correct impaired energetics, simultaneously treating angina and heart failure symptoms. We review the principles underlying the safe use of such agents, beginning with the prototype drug perhexiline maleate, which despite complex pharmacokinetics and potential hepato- or neuro-toxicity has emerged as an attractive management option in many "complicated" cases of angina pectoris.|
|Keywords:||Angina; Perhexiline; Myocardial metabolism|
|Rights:||© Springer Science+Business Media New York 2016|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.